Connect with us

Industry

Thousands of cannabis firms reject 0.03% THC proposals

Published

on

Over 1,000 businesses have warned the move would be a "disaster"

Leading cannabis trade bodies have rejected a controversial proposed THC limit on hemp and CBD products, deepening an industry rift.

Earlier this week, the Association for the Cannabinoid Industry, Centre for Medical Cannabis and the Conservative Drug Policy Reform Group released a paper which suggested a 0.03 percent THC limit should be adopted by the Home Office.

Under the proposals, CBD products and hemp strains below those levels would be exempted from controlled status.

The paper’s authors set out to address what they described as “widespread confusion” at the UK regulations – but industry leaders are not satisfied with the approach.

A letter by four key industry bodies representing over 1,000 businesses warns the move would be a “disaster” and is too stringent to allow the UK hemp sector to grow.

The letter is co-signed by the British Hemp Alliance, Cannabis Trade Association, Northern Ireland Hemp Association and Scottish Hemp Association. It reads: “A 0.03 percent limit to import flowers and leaves would be incredibly restrictive and destroy a domestic industry worth up to £300 million in the UK.

“With the forecasted increase in temperatures and droughts, the THC level is only going to naturally rise in all cannabis varieties over time.”

Instead, they argue, the industry should be pushing Whitehall to adopt a more liberal one percent limit as a “logical way forward” to keep “the UK competitive with the rest of the world”.

The proposed 0.03 percent limit – or 21 micrograms per day – is part of a wider set of policy proposals aimed at harmonising UK regulation.

But proposed changes to how certain consumer CBD products are classified and regulated were also met with opposition for not going far enough: “CBD as a food supplement should be available to anyone who wants it, and all hemp extracts and foods up to 0.2 percent THC should be completely removed from the misuse of drugs act and exempt from controlled drug handling licenses.

“While we support setting a maximum daily limit for THC consumption in hemp products, we cannot support 0.03 percent as a maximum in food supplements, nor of the idea of Schedule 5 cannabis medicines for products containing 0.03-0.2 percent THC.”

The letter goes on to say any policy changes must take into account an upcoming white paper being drafted by Professor Mike Barnes.

The authors of the original report have been contacted for comment.

Industry

Isle of Man launches medical cannabis export sector

The Isle of Man is open for business to the medical cannabis industry.

Published

on

The move could 250 new jobs and generate £3 million a year for the island

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3 million a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

The island’s regulator – the Gambling Supervision Commission – has set out conditions for the licensing of high-THC cannabis and hemp.

Enterprise minister Laurence Skelly said: “The growing global medicinal cannabis market provides significant opportunity for economic development in the Isle of Man, and the new regulatory framework and guidance will offer stringent and flexible licensing of a broad range of cannabis products, which ranges from outdoor grown industrial hemp to indoor grown medicinal products.

“The Isle of Man Government has every confidence that the GSC will provide a world class regulatory structure required to regulate this new and complex industry.

The Isle of Man wants to be a major player in Europe’s growing medical cannabis industry.

“I am delighted to welcome licence applications and look forward to attracting quality businesses to the Island, transforming the cannabis export sector into a key contributor to the Isle of Man’s post-Covid economic recovery.”

The self-governing British Crown Dependency, which has a population of 83,000, approved new medical cannabis laws in January.

The island’s parliament – the Tynwald – moved to attract the industry to its shores after a public consultation showed 95 percent of residents were in favour of the policy.

Mark Rutherford, director of policy at the island’s regulator, said: “The GSC already has a sophisticated framework for supervising gambling.

‘We have worked carefully to apply the best of that framework to the risks in the new sector and we have educated ourselves in the technical areas that are new to us.

“What we now have will ensure that all stakeholders will be competent, crime free and capable of building a sector that is safe, trusted and efficient.

“As regulators, we aspire to put our regulatory umbrella above as many consumers as possible so that they can benefit from regulations that are well thought out and properly supervised.

“Years of prohibition mean that the markets in which our licensees will be participating are still in their infancy and still contain many uncertainties.

“To address this situation, it is our aim to ensure that consumers who purchase Isle of Man products will be able to understand exactly what their product contains through accurate labelling and independent testing.

“The GSC recognises there are many stakeholders in this newly created field and intends to extend its ethos of cooperation with other government authorities into its approach to cannabis regulation.”

Continue Reading

Industry

Always Pure Organics announces major expansion to meet demand

Construction is underway on a new 10,000 square foot warehouse

Published

on

The APO team has grown from three people to over 50 staff members

Sponsored feature

Always Pure Organics has announced that construction is underway on its new 10,000 square foot warehouse as part of a major expansion, here they reveal all.

At Always Pure Organics, our mission is to accelerate the global access, acceptance and understanding of cannabinoids and their wide benefits.

We’re proud to take you ‘behind the scenes’, where you’ll meet our team and gain a further understanding of how we serve our clients and facilitate growth of the cannabinoid industry.

 

One of our latest projects involves expanding our Always Pure Organics facilities. Renovations began in early June and we are excited for the extra space that the expansion will afford our lab and operation teams.

Our CEO Gavin Ogilvie commented on the project: “We’re so proud of the growth we’ve achieved. In two and a half years the business has gone from three people working out of a bedroom to over 50 team members servicing 500 global clients.

“With this comes a responsibility to our customers and partners to continue to deliver the personal, quick and hands-on service that we have done historically. With the increasing demand placed on our operations and production teams this was becoming a mounting challenge. Therefore, we have invested heavily to overhaul and upsize our warehouse and clean rooms. This week we began the construction in our new 10,000 square foot warehouse.

“We want to offer the best products, with more variety, more quickly and with a better user experience than any of our competitors. This is just one step in achieving that.”

Always Pure Organics Specialist Manufacturer of Cannabis Based Products.

We offer the highest quality wholesale legal cannabis and cannabinoid products, as bulk ingredients, bulk products, white label, and bespoke formulations. This is coupled with regulatory and legal expertise and supported by delivery globally.

Our unique bespoke formulation products allow our customers to create their own product from scratch, whilst we provide the regulatory and product knowledge, as well as production of the product.

To find out more about how Always Pure Organics can support your business on its CBD journey visit alwayspureorganics.com or follow us on LinkedIn and YouTube.

Continue Reading

Industry

The UK cannabis veterans taking on the industry’s big beasts

AltoVerde wants to shake things up in the industry which it believes has gone from counter-culture to corporate.

Published

on

The company plans to open a 10,000+ square metre cultivation plant in Macedonia

Meet the UK executive and cannabis veteran, aiming to take on Europe and North America’s established industry titans.

Mitesh Makwana is the director of AltoVerde, a start up company looking to establish itself as one of the continent’s big players.

The race is on to put roots down in Europe with several countries expected to expand patient access in the coming years – and even open up adult use markets.

Huge companies from across the pond like Tilray, Aurora and Bedrocan have already got boots on the ground, buying up companies and starting operations in places like Denmark and Portugal.

AltoVerde is aiming to be the new kid on the block and wants to shake things up in an industry which it believes has gone from counter-culture to corporate.

Makwana told Cannabis Health: “It’s become a completely different scene. We know that there might be a view that us industry veterans aren’t ready to take on this new market but we just plan to get our heads down and get on with what we know best.

“We understand that there are big regulatory hurdles, but ultimately there is one goal: getting a good end product to consumers at a fair price.”

This team of ‘veterans’, some of whom have almost two decades experience in the industry, have been in the game since paraphernalia and souvenir seeds were the only way to make money out of cannabis in Europe.

Mitesh Makwana

But things are changing. The medical cannabis sector in Europe is forecast to explode over the next few years and companies set up and ready to go when liberalisation happens stand to make a fortune.

Makwana said: “The team and our roots set us apart from the rest of the industry.

“Many of the people involved with company have been active in this sector for several years, people who’ve spent years honing their expertise in cultivation, breeding, plantation management, clinical trials, chemistry and extraction.

“This plant has a lot of amazing properties and we’re passionate about unlocking them for consumers and patients.”

The company has already completed an initial funding round and is planning a private subscription to raise further capital in the near future.

Deals to begin two manufacturing operations in Europe, including a 10,000+ square metre cultivation plant in Macedonia, are nearing completion and the company has longer term ambitions to carry out its own clinical trials.

It’s early days but the company has set out a five-year growth plan and is targeting £13.1m in inward investment.

Makwana told Cannabis Health, AltoVerde, which is headquartered in the UK, will be involved from seed to distribution and will respond to change in the market and regulations.

He said: “We’re setting ourselves up to be able to adjust to the way market demands shift over the coming years.

“With our expertise we know we can satisfy demand from the medicinal and wellbeing markets.

“We’re positioning ourselves up to take advantage whichever way regulations go and however the market changes.

“With our experience we know we can change and adapt.”

 

Continue Reading

Trending